NAT1 Genotypes Do not Predict Response to Mesalamine in Patients with Ulcerative Colitis
نویسندگان
چکیده
منابع مشابه
NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis.
BACKGROUND 5- Aminosalicylic acid (5-ASA) is metabolised in colonic mucosa by N-acetyltransferase 1 (NAT1). Common genetic polymorphisms in this enzyme result in rapid or slow acetylation. 5-ASA treatment causes side effects in up to 10 % of patients with ulcerative colitis (UC). We therefore determined genetic variations of NAT1 in patients with UC and looked for a possible association with th...
متن کاملGenetic variants in cellular transport do not affect mesalamine response in ulcerative colitis
BACKGROUND AND AIMS Mesalamine is commonly used to treat ulcerative colitis (UC). Although mesalamine acts topically, in vitro data suggest that intracellular transport is required for its beneficial effect. Genetic variants in mucosal transport proteins may affect this uptake, but the clinical relevance of these variants has not been studied. The aim of this study was to determine whether vari...
متن کاملWhy do patients with ulcerative colitis relapse?
To determine the factors responsible for ulcerative colitis relapse a cohort of 92 patients (18 to 78 years, 50 men) with clinically inactive disease have been followed for over 48 weeks. At 12 weekly intervals patients were asked, by means of standardised questionnaires, about infections, compliance with maintenance medication, new drug treatment, dietary changes, episodes of non-bloody diarrh...
متن کاملMesalamine treatment mimicking relapse in a child with ulcerative colitis.
BACKGROUND There are reports on mesalamine-induced bloody diarrhea mimicking ulcerative colitis (UC) relapse, mostly in adults. METHODS Herein we present a case of a child with UC who developed relapse of hemorrhagic colitis related to mesalamine. RESULTS A 10-year-old girl developed severe symptoms mimicking UC relapse 3 weeks after introduction of mesalamine therapy. After mesalamine was ...
متن کاملMucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
BACKGROUND AND AIMS Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Zeitschrift für Gastroenterologie
سال: 2008
ISSN: 0044-2771,1439-7803
DOI: 10.1055/s-2007-963673